Cognition Therapeutics (NASDAQ:CGTX) Earns “Buy” Rating from B. Riley

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating restated by investment analysts at B. Riley in a note issued to investors on Thursday, Benzinga reports. They presently have a $5.00 price objective on the stock. B. Riley’s price target would suggest a potential upside of 177.78% from the stock’s current price.

Separately, Oppenheimer restated an “outperform” rating and set a $9.00 price objective on shares of Cognition Therapeutics in a research note on Wednesday.

Cognition Therapeutics Trading Down 1.1 %

Shares of Cognition Therapeutics stock traded down $0.02 during trading hours on Thursday, reaching $1.80. The stock had a trading volume of 95,372 shares, compared to its average volume of 213,365. The firm has a 50 day simple moving average of $2.08 and a two-hundred day simple moving average of $1.65. The firm has a market capitalization of $70.20 million, a price-to-earnings ratio of -2.08 and a beta of 1.67. Cognition Therapeutics has a 1 year low of $0.90 and a 1 year high of $3.49.

Hedge Funds Weigh In On Cognition Therapeutics

A number of hedge funds have recently modified their holdings of CGTX. Steward Financial Group LLC purchased a new position in shares of Cognition Therapeutics during the third quarter valued at $58,000. BlackRock Inc. lifted its position in shares of Cognition Therapeutics by 54.8% in the second quarter. BlackRock Inc. now owns 58,417 shares of the company’s stock worth $107,000 after buying an additional 20,678 shares during the last quarter. Two Sigma Investments LP increased its stake in shares of Cognition Therapeutics by 91.0% in the fourth quarter. Two Sigma Investments LP now owns 46,620 shares of the company’s stock worth $98,000 after purchasing an additional 22,213 shares during the period. Captrust Financial Advisors bought a new position in shares of Cognition Therapeutics in the third quarter worth about $95,000. Finally, Baird Financial Group Inc. increased its stake in Cognition Therapeutics by 100.0% during the third quarter. Baird Financial Group Inc. now owns 40,786 shares of the company’s stock valued at $77,000 after acquiring an additional 20,393 shares during the period. 43.35% of the stock is currently owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.